Comment from ALS United

Summary: ALS United, a nationwide partnership of nonprofit organizations, supports the FDA's proposed pilot program for AI-enabled optimization of early-phase clinical trials. They argue that while real-time data sharing can accelerate development for rapidly progressive diseases like ALS, the program must include diverse sponsors, invest in biomarker infrastructure, ensure human oversight of AI decisions, and involve patient organizations in governance.